Abstract 806P
Background
MBO is a severe complication of advanced cancer. An interprofessional ambulatory outpatient MBO program with nurse-led proactive call management was established to support patients (pts) with gynecologic cancers at Princess Margaret Cancer Centre, showing reduction of hospitalization needs and improved outcomes.
Methods
“My Bowels on Track” is a pilot ambulatory electronic monitoring program for pts with gynecologic cancers with or at risk of MBO. Educational materials, secure messaging systems and ≤13 questions (Q) are offered weekly/biweekly. Based on Q answers, an alerting system flags pts with symptoms (yellow and red alerts indicate moderate and high concern, respectively) and no response to Q. Pts are contacted by nurses following clinical or compliance alerts. The primary objective is to assess the adherence (≥70% Q completion considered adherent) on the first two months on the program. A secondary objective is to assess the sensitivity of the alerts to trigger recommendations. Adherence was calculated as a rate. Alert sensitivity was assessed with a generalized estimation equation.
Results
40 pts enrolled between 08/21 and 09/22. Median age was 64.5 years (range 29-79). Primary diagnosis was ovarian (75%), uterine (17.5%) or cervical (7.5%) cancer, and 92.5% of pts were on systemic therapy. Clinical/radiological active MBO was present in 30% and 12.5% of pts prior to and at enrollment, respectively. Median duration of the program was 55 days (range 8-121). The two-month adherence was 65% (95% CI 50-80%), and the overall adherence was 60% (95% CI 43-75%). 65 symptom related alerts (75% yellow; 25% red) were reported in 60% (24/40) of pts. There were 59 recommendations triggered by alerts (29% dietary, 22% laxatives, 20% clinic assessment, 16% other medication, 8% emergency department referral, 5% other). The sensitivity of the alerts to trigger actions was 72% (95% CI 58-82%).
Conclusions
This pilot electronic MBO monitoring program with real-time patient reported outcome assessment was feasible, with 65% adherence at two months. Based on questionnaire answers an alerting system flagged symptoms of concern in 60% of participants, with a high sensitivity to provide actions or recommendations as a response to alerts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
ASCO Conquer Cancer Young Investigator Award (Ainhoa Madariaga).
Disclosure
A. Madariaga Urrutia: Financial Interests, Personal, Advisory Role: AstraZeneca, GSK, PharmaMar; Financial Interests, Personal, Invited Speaker: Clovis, AstraZeneca, GSK. N.C. Dhani: Financial Interests, Speaker, Consultant, Advisor: AstraZeneca, Merck. R. Grant: Financial Interests, Personal, Advisory Board: AstraZeneca, Eisai, Knight Therapeutics; Financial Interests, Personal, Other, Graduate scholarship: Pfizer; Non-Financial Interests, Advisory Role: Tempus, Incyte. V. Bowering: Financial Interests, Personal, Advisory Board: AstraZeneca; Non-Financial Interests, Personal, Advisory Board: GSK, AstraZeneca. A.M. Oza: Non-Financial Interests, Personal, Advisory Board: AstraZeneca, GSK, Clovis; Other, Personal, Research Funding: AstraZeneca, GSK, Clovis; Non-Financial Interests, Personal, Leadership Role: Ozmosis Research. A. Berlin: Other, Personal, Advisory Role: AbbVie, Ferring, Astellas Pharma. S. Lheureux: Financial Interests, Personal, Advisory Board: AstraZeneca, GSK, Eisai, Merck, Novartis; Financial Interests, Personal, Invited Speaker: GSK, Roche; Financial Interests, Institutional, Research Grant, Academic trial: GSK; Financial Interests, Institutional, Local PI: Repare Therapeutics, Merck, AstraZeneca, Regeneron, GSK, Roche, Seagen; Financial Interests, Institutional, Research Grant: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11